ERBB2 and neoplasm: By analyzing FFPE-DNA from tumor specimens with ddPCR, ERBB2 amplification was found in 7/28 (25%) patients; 5 in HER2 3+, 1 in HER2 2+, and 1 in HER2 0–1+ (Table 4).